¼¼°èÀÇ ³ì³ó±Õ °¨¿°Áõ Ä¡·á ½ÃÀå
Pseudomonas Aeruginosa Infection Treatment
»óǰÄÚµå : 1784063
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 273 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,218,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,655,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

³ì³ó±Õ °¨¿°Áõ Ä¡·á ¼¼°è ½ÃÀåÀº 2030³â±îÁö 28¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 23¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ³ì³ó±Õ °¨¿°Áõ Ä¡·á ¼¼°è ½ÃÀåÀº 2024-2030³â ºÐ¼® ±â°£ µ¿¾È CAGR 3.3%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 28¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ º´¿ë¿ä¹ýÀº CAGR 2.7%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á±îÁö 18¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ´Üµ¶¿ä¹ý ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 4.5%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 6¾ï 2,110¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 6.0%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ³ì³ó±Õ °¨¿°Áõ Ä¡·á ½ÃÀåÀº 2024³â¿¡ 6¾ï 2,110¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 5¾ï 4,260¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 6.0%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 1.3%¿Í 2.4%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 1.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°è ³ì³ó±Õ °¨¿°Áõ Ä¡·á ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ Á¤¸®

³ì³ó±ÕÀÌ ¿Ö °Ç°­ °ü¸®¿¡¼­ Áß¿äÇÑ °ü½É»çÀΰ¡?

³ì³ó±ÕÀº Ç×»ýÁ¦¿¡ ´ëÇÑ ³»¼ºÀÌ °­ÇÏ°í ¸é¿ª·ÂÀÌ ¾àÇÑ È¯ÀÚ¿¡°Ô ½É°¢ÇÑ °¨¿°À» ÀÏÀ¸Å³ ¼ö Àֱ⠶§¹®¿¡ ƯÈ÷ º´¿ø ¹× ÀÇ·á ȯ°æ¿¡¼­ °¡Àå °­·ÂÇÑ ±âȸÁÖÀÇÀûÀÎ º´¿ø±Õ Áß ÇϳªÀÔ´Ï´Ù. ÀÌ ±×¶÷À½¼º±ÕÀº º´¿ø ³» Æó·Å, Ç÷·ù°¨¿°, ¿ä·Î°¨¿°, ³¶Æ÷¼º¼¶À¯Áõ ȯÀÚÀÇ ¸¸¼º Æó°¨¿°À» À¯¹ßÇÏ´Â °ÍÀ¸·Î À¯¸íÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ³»¼º ¸ÞÄ¿´ÏÁòÀº ³»¼º À¯ÀüÀÚ¸¦ ȹµæÇÏ´Â ´É·Â°ú °áÇÕÇÏ¿© Ä¡·á¸¦ Á¡Á¡ ´õ ¾î·Æ°Ô ¸¸µé°í ÀÖÀ¸¸ç, »õ·Î¿î Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ²÷ÀÓ¾ø´Â Ž»öÀÌ ÇÊ¿äÇÕ´Ï´Ù. ¹ÙÀÌ¿ÀÇʸ§À» Çü¼ºÇÏ´Â º´¿ø±ÕÀÇ ´É·ÂÀº Ä¡·á¸¦ ´õ¿í º¹ÀâÇÏ°Ô ¸¸µé°í, ¹ÙÀÌ¿ÀÇʸ§°ú °ü·ÃµÈ °¨¿°Àº º»ÁúÀûÀ¸·Î Ç×»ýÁ¦ ¹× ¼÷ÁÖÀÇ ¸é¿ª ¹ÝÀÀ¿¡ ´ëÇÑ ÀúÇ×¼ºÀÌ ³ô±â ¶§¹®¿¡ ´õ¿í º¹ÀâÇØÁý´Ï´Ù. ´ÙÁ¦³»¼º(MDR) ³ì³ó±ÕÀÇ È®»êÀº ÀÔ¿ø ±â°£°ú »ç¸Á·üÀ» Áõ°¡½ÃÄÑ ÀÇ·á ½Ã½ºÅÛ¿¡ Å« ºÎ´ãÀ» ÁÖ°í ÀÖ½À´Ï´Ù. ±× °á°ú, »õ·Î¿î Ç×±ÕÁ¦, º´¿ë¿ä¹ý, ¹ÚÅ׸®¿ÀÆÄÁö ¿ä¹ý, ´ÜŬ·ÐÇ×ü µîÀÇ ´ëü Ä¡·á¹ýÀ» À§ÇØ ¸¹Àº ¿¬±¸ ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖ½À´Ï´Ù. ÀÌ º´¿øÃ¼¿ÍÀÇ ½Î¿òÀÌ ½Ã±ÞÇÑ »óȲ¿¡¼­ Á¶±â ¹ß°ß°ú Ç¥Àû Ä¡·á¸¦ À§ÇÑ ÀǾàǰ ¿¬±¸ °³¹ß ¹× Áø´ÜÀÇ ¹ßÀü¿¡ ´ëÇÑ ÅõÀÚ¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

Ç×»ýÁ¦ Çõ½Å°ú ³»¼º ¹®Á¦´Â ¾î¶»°Ô ½ÃÀåÀ» Çü¼ºÇϰí Àִ°¡?

Ç×»ýÁ¦ ³»¼º À§±â´Â ³ì³ó±Õ °¨¿°¿¡ ´ëÇÑ »õ·Î¿î Ä¡·á Àü·«À» °³¹ßÇÏ´Â µ¥ Å« ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. °ú°Å Ä¡·áÀÇ ÁÖ·ù¿´´ø ¥â-¶ôްè, ¾Æ¹Ì³ë±Û¸®ÄÚ»çÀ̵å°è, Ç÷ç¿À·ÎÄû³î·Ð°è µî ±âÁ¸ Ç×»ýÁ¦´Â ³»¼º·üÀÇ Áõ°¡·Î ÀÎÇØ È¿°ú°¡ ¶³¾îÁö°í ÀÖ½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ Á¦¾à»çµéÀº ¼¼±ÕÀÇ ¹æ¾î±âÀüÀ» ±Øº¹Çϱâ À§ÇØ »õ·Î¿î ¥â-¶ôŸ¸¶Á¦ ¾ïÁ¦Á¦ ¹× º´¿ë¾à¹° °³¹ß¿¡ Èû¾²°í ÀÖ½À´Ï´Ù. ÃÖ±Ù µµÀÔµÈ ¼¼ÇÁÆ®·ÎÀÜ-ŸÁ¶¹Úްú ¼¼ÇÁŸµðÁü-¾Æºñ¹ÚŽÀº ¾àÁ¦ ³»¼º ½´µµ¸ð³ª½º °¨¿° Ä¡·á¿¡ À¯¸ÁÇϸç, ±âÁ¸ Ä¡·á¹ýÀÌ ½ÇÆÐÇÑ °æ¿ì »õ·Î¿î Èñ¸ÁÀ» °¡Á®´ÙÁÖ°í ÀÖ½À´Ï´Ù. ÇÑÆí, Äݸ®½ºÆ¾À» Æ÷ÇÔÇÑ Æú¸®¹Í½Å °è¿­ ¾à¹°¿¡ ´ëÇÑ ¿¬±¸´Â ½Åµ¶¼º ¿ì·Á´Â ÀÖÁö¸¸, MDR ±ÕÁÖ¿¡ ´ëÇÑ ¸¶Áö¸· ¼±ÅÃÁö Áß Çϳª¶ó´Â Á¡¿¡¼­ ´Ù½Ã±Ý °ü½ÉÀ» ¸ðÀ¸°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÆÄÁö¿ä¹ý(¹ÚÅ׸®¿ÀÆÄÁö¸¦ ÀÌ¿ëÇÏ¿© ¼¼±ÕÀ» °ø°ÝÇÏ¿© ÆÄ±«ÇÏ´Â Ä¡·á¹ý)µµ Ȱ¹ßÈ÷ ÁøÇàµÇ°í ÀÖÀ¸¸ç, Ç×»ýÁ¦ ´ëü ¶Ç´Â º¸Á¶Á¦·Î¼­ÀÇ °¡´É¼ºÀ» ÀÓ»ó½ÃÇèÀ» ÅëÇØ °ËÅäÇϰí ÀÖ½À´Ï´Ù. Ç×±Õ ÆéŸÀ̵å, Àΰø ³ª³ëÀÔÀÚ, Äõ¶÷¼¾½Ì ¾ïÁ¦Á¦ °³¹ßµµ Çõ½ÅÀûÀÎ Ä¡·á Á¢±Ù¹ýÀ¸·Î °ËÅäµÇ°í ÀÖ½À´Ï´Ù. ¾àÁ¦ ³»¼ºÀÌ °è¼Ó ÁøÈ­ÇÏ´Â °¡¿îµ¥, FDA¿Í EMA µî ±ÔÁ¦ ±â°üÀº ½Å¼ÓÇÑ ÇØ°áÃ¥ÀÇ Çʿ伺À» ÀνÄÇÏ°í »õ·Î¿î Ç×±ÕÁ¦ ½ÂÀÎ ÀýÂ÷¸¦ °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù.

³ì³ó±Õ Ä¡·á¿¡¼­ Áø´Ü°ú Á¤¹ÐÀÇ·á´Â ¾î¶² ¿ªÇÒÀ» Çϴ°¡?

³ì³ó±Õ °¨¿°À» È¿°úÀûÀ¸·Î °ü¸®Çϱâ À§Çؼ­´Â ½Å¼ÓÇϰí Á¤È®ÇÑ Áø´ÜÀÌ ÇʼöÀûÀÔ´Ï´Ù. Ä¡·á°¡ ´Ê¾îÁö¸é ƯÈ÷ ¸é¿ª·ÂÀÌ ¾àÇÑ È¯ÀÚ¿¡°Ô´Â ½É°¢ÇÑ ÇÕº´ÁõÀ» À¯¹ßÇÒ ¼ö Àֱ⠶§¹®ÀÔ´Ï´Ù. PCR ±â¹Ý ºÐ¼® ¹× Â÷¼¼´ë ¿°±â¼­¿­ ºÐ¼®(NGS)À» Æ÷ÇÔÇÑ ºÐÀÚÁø´Ü ¹æ¹ýÀÇ º¸±ÞÀº º´¿øÃ¼ °ËÃâ¿¡ Çõ¸íÀ» °¡Á®¿ÔÀ¸¸ç, ÀÓ»óÀǰ¡ ³»¼º ¸¶Ä¿¸¦ ½Äº°ÇÏ°í ±×¿¡ µû¶ó Ç×»ýÁ¦ ¿ä¹ýÀ» Á¶Á¤ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, MALDI-TOF¿Í °°Àº Áú·® ºÐ¼® ±â¼úÀº ¹Ì»ý¹° °Ë»ç½Ç¿¡¼­ ÀÓ»ó »ùÇÿ¡¼­ Á÷Á¢ ½´µµ¸ð³ª½º ¼ÓÀ» ½Å¼ÓÇÏ°Ô ½Äº°ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀΰøÁö´É(AI)°ú ¸Ó½Å·¯´×À» Áø´ÜÇп¡ ÅëÇÕÇÏ´Â °ÍÀº ¿¹Ãø ¸ðµ¨ÀÌ ¹Ì»ý¹° ³»¼º ÆÐÅÏ¿¡ µû¶ó ÀÓ»óÀǰ¡ °¡Àå È¿°úÀûÀÎ Ä¡·á Àü·«À» ¼±ÅÃÇÏ´Â µ¥ µµ¿òÀÌ µÇ±â ¶§¹®¿¡ À¯ÀÍÇÏ´Ù´Â °ÍÀÌ ÀÔÁõµÇ¾ú½À´Ï´Ù. °³º°È­ Á¢±Ù¹ý¿¡¼­´Â Ç¥Àû Ä¡·á¹ýÀ» ¼±ÅÃÇϱâ Àü¿¡ ȯÀÚÀÇ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È, ¸é¿ª ¹ÝÀÀ, ¹ÚÅ׸®¾Æ ±ÕÁÖÀÇ Æ¯¼ºÀ» °í·ÁÇϱ⠶§¹®¿¡ Á¤¹ÐÀÇ·á´Â ÀÌ ºÐ¾ß¿¡¼­ Á¡Á¡ ´õ °ü·Ã¼ºÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. Ç×±ÕÁ¦ ½ºÆ©¾îµå½Ê ÇÁ·Î±×·¥ ½ÃÀåÀÌ È®´ëµÊ¿¡ µû¶ó º´¿øµéÀº Ä¡·á È¿°ú¸¦ ÃÖÀûÈ­ÇÏ°í ±¤¹üÀ§ Ç×»ýÁ¦ ¿À³²¿ëÀ» ¹æÁöÇϱâ À§ÇØ ÀÚµ¿ °¨¼ö¼º °Ë»ç ¹× AI ±â¹Ý Ç×»ýÁ¦ °áÁ¤ Áö¿ø µµ±¸¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. Áø´Ü ±â¾÷°ú Á¦¾à ±â¾÷ °£ÀÇ Çù·ÂÀÌ ½ÉÈ­µÊ¿¡ µû¶ó ³ì³ó±Õ Ä¡·áÀÇ ¹Ì·¡´Â º¸´Ù Ÿ°ÙÀÌ ¸íÈ®Çϰí, µ¥ÀÌÅÍ ±â¹ÝÀ̸ç, ȯÀÚ ¸ÂÃãÇüÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

³ì³ó±Õ °¨¿°Áõ Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ¹«¾ùÀΰ¡?

¼¼°è ³ì³ó±Õ °¨¿°Áõ Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀº ´ÙÁ¦³»¼º ±ÕÁÖ Áõ°¡, º´¿ø³» °¨¿° Áõ°¡, Ç×±ÕÁ¦ °³¹ßÀÇ ÁøÀü µî ¿©·¯ ¿äÀÎÀ¸·Î ÀÎÇØ ¹ß»ýÇÕ´Ï´Ù. ±âÁ¸ Ä¡·á¹ýÀ¸·Î´Â ³»¼º±Õ¿¡ ´ëÇÑ È¿°ú°¡ ºÒÃæºÐÇϱ⠶§¹®¿¡ »õ·Î¿î Ç×»ýÁ¦ ¹× º´¿ë¿ä¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ºÐÀÚÁø´Ü ±â¼ú ¹× ½Å¼ÓÇÑ º´¿øÃ¼ ŽÁö µµ±¸ÀÇ È®´ëµµ Á¶±â¿¡ Á¤È®ÇÑ °³ÀÔÀ» °¡´ÉÇϰÔÇÔÀ¸·Î½á ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¾Ï ȯÀÚ, ÀÌ½Ä È¯ÀÚ, ¸¸¼º È£Èí±âÁúȯ ȯÀÚ µî ¸é¿ª °áÇÌ È¯ÀÚÀÇ Áõ°¡·Î ÀÎÇØ È¿°úÀûÀÎ Ä¡·á ¿É¼ÇÀÇ Çʿ伺ÀÌ ´õ¿í Ä¿Áö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, º´¿ø ¹× ÀÇ·á ½Ã¼³¿¡¼­ Ç×±ÕÁ¦ °ü¸® ÇÁ·Î±×·¥¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó °¨¼ö¼º À¯µµ Ä¡·á¹ýÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí Â÷¼¼´ë Ç×»ýÁ¦ ¹× º¸Á¶ ¿ä¹ýÀÇ »ç¿ëÀÌ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ¹ÚÅ׸®¿ÀÆÄÁö Ä¡·á, ¼÷ÁÖ ÁöÇâÀû Ä¡·á, ¸é¿ªÁõ°­ »ý¹°ÇÐÀû Á¦Á¦ µî ´ëü Ä¡·á¹ýÀÇ ¿¬±¸·Î ±âÁ¸ Ç×»ýÁ¦°¡ µèÁö ¾Ê´Â °¨¿°Áúȯ¿¡ ´ëÀÀÇÒ ¼ö ÀÖ´Â »õ·Î¿î ±æÀÌ ¿­¸®°í ÀÖ½À´Ï´Ù. ±ÔÁ¦ ´ç±¹ÀÇ Áö¿ø°ú ¼¼°èº¸°Ç±â±¸(WHO)ÀÇ AMR¿¡ °üÇÑ ¼¼°èÇൿ°èȹ°ú °°Àº Ç×±ÕÁ¦ ³»¼º ´ëÀÀÀ» À§ÇÑ ¼¼°è ÀÌ´Ï¼ÅÆ¼ºê´Â ½Å¾à °³¹ß ¹× °¨¿° ´ëÃ¥¿¡ ´ëÇÑ ÅõÀÚ¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¹Î°ü ÀÌÇØ°ü°èÀÚµéÀÇ ÀÚ±Ý Áö¿øÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Á¦¾àȸ»çµéÀº Â÷¼¼´ë Ç×»ýÁ¦, Áø´Ü¾à, º¸Á¶¿ä¹ý °³¹ß¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖÀ¸¸ç, ³ì³ó±Õ Ä¡·á ½ÃÀåÀº ÇâÈÄ ¸î ³â µ¿¾È Áö¼ÓÀûÀÎ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.

ºÎ¹®

Ä¡·á À¯Çü(º´¿ë¿ä¹ý, ´Üµ¶¿ä¹ý), Åõ¿© °æ·Î(°æ±¸, °æºñ, Á¤¸Æ³»)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

¿ì¸®´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM ¹× ¾÷°è °íÀ¯ÀÇ SLMÀ» Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹üÀ» µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Pseudomonas Aeruginosa Infection Treatment Market to Reach US$2.8 Billion by 2030

The global market for Pseudomonas Aeruginosa Infection Treatment estimated at US$2.3 Billion in the year 2024, is expected to reach US$2.8 Billion by 2030, growing at a CAGR of 3.3% over the analysis period 2024-2030. Combination Therapy, one of the segments analyzed in the report, is expected to record a 2.7% CAGR and reach US$1.8 Billion by the end of the analysis period. Growth in the Monotherapy segment is estimated at 4.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$621.1 Million While China is Forecast to Grow at 6.0% CAGR

The Pseudomonas Aeruginosa Infection Treatment market in the U.S. is estimated at US$621.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$542.6 Million by the year 2030 trailing a CAGR of 6.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.8% CAGR.

Global Pseudomonas Aeruginosa Infection Treatment Market - Key Trends & Drivers Summarized

Why Is Pseudomonas Aeruginosa a Critical Concern in Healthcare?

Pseudomonas aeruginosa is one of the most formidable opportunistic pathogens, particularly in hospital and healthcare settings, due to its high resistance to antibiotics and its ability to cause severe infections in immunocompromised patients. This gram-negative bacterium is notorious for causing hospital-acquired pneumonia, bloodstream infections, urinary tract infections, and chronic lung infections in individuals with cystic fibrosis. Its intrinsic resistance mechanisms, combined with its ability to acquire additional resistance genes, have made treatment increasingly challenging, necessitating a continuous search for new therapeutic options. The pathogen’s ability to form biofilms further complicates treatment, as biofilm-associated infections are inherently more resistant to antibiotics and host immune responses. The rising prevalence of multidrug-resistant (MDR) Pseudomonas aeruginosa has placed a heavy burden on healthcare systems, increasing the length of hospital stays and mortality rates. As a result, significant research efforts are being directed toward novel antimicrobial agents, combination therapies, and alternative treatment modalities such as bacteriophage therapy and monoclonal antibodies. The urgency to combat this pathogen has fueled investments in both pharmaceutical R&D and diagnostic advancements aimed at early detection and targeted therapy.

How Are Antibiotic Innovations and Resistance Challenges Shaping the Market?

The antibiotic resistance crisis has been a major driving force behind the development of new treatment strategies for Pseudomonas aeruginosa infections. Traditional antibiotics such as beta-lactams, aminoglycosides, and fluoroquinolones, once the mainstay of treatment, have shown decreasing efficacy due to rising resistance rates. In response, pharmaceutical companies have been working on developing novel beta-lactamase inhibitors and combination drugs to overcome bacterial defense mechanisms. The recent introduction of ceftolozane-tazobactam and ceftazidime-avibactam has shown promise in treating drug-resistant Pseudomonas infections, offering new hope where conventional treatments fail. Meanwhile, research into polymyxins, including colistin, has gained renewed interest, despite concerns over nephrotoxicity, as it remains one of the last-resort options for MDR strains. Additionally, phage therapy-using bacteriophages to target and destroy bacteria-has gained momentum, with clinical trials investigating its potential as an alternative or adjunct to antibiotics. The development of antimicrobial peptides, engineered nanoparticles, and quorum-sensing inhibitors is also being explored as innovative treatment approaches. As drug resistance continues to evolve, regulatory agencies such as the FDA and EMA are expediting the approval process for new antimicrobial agents, recognizing the need for urgent solutions.

What Role Do Diagnostics and Precision Medicine Play in Pseudomonas Aeruginosa Treatment?

Rapid and accurate diagnosis is essential for effectively managing Pseudomonas aeruginosa infections, as delayed treatment can lead to severe complications, particularly in immunocompromised patients. The growing adoption of molecular diagnostics, including PCR-based assays and next-generation sequencing (NGS), has revolutionized pathogen detection, enabling clinicians to identify resistance markers and tailor antibiotic regimens accordingly. Additionally, mass spectrometry techniques such as MALDI-TOF have gained traction in microbiology laboratories, offering rapid identification of Pseudomonas species directly from clinical samples. The integration of artificial intelligence (AI) and machine learning in diagnostics is also proving beneficial, as predictive models help clinicians choose the most effective treatment strategy based on microbial resistance patterns. Precision medicine is becoming increasingly relevant in this space, as personalized approaches consider the patient’s microbiome, immune response, and bacterial strain characteristics before selecting targeted therapies. As the market for antimicrobial stewardship programs grows, hospitals are investing in automated susceptibility testing and AI-driven antibiotic decision-support tools to optimize treatment efficacy and prevent the misuse of broad-spectrum antibiotics. With increasing collaboration between diagnostic companies and pharmaceutical firms, the future of Pseudomonas aeruginosa treatment is expected to be more targeted, data-driven, and patient-specific.

What Are the Key Factors Driving the Growth of the Pseudomonas Aeruginosa Infection Treatment Market?

The growth in the global Pseudomonas aeruginosa infection treatment market is driven by several factors, including the rising prevalence of multidrug-resistant strains, increasing hospital-acquired infections, and advancements in antimicrobial drug development. The demand for novel antibiotics and combination therapies has surged, as conventional treatment options are proving insufficient against resistant strains. The expansion of molecular diagnostic technologies and rapid pathogen detection tools has also contributed to market growth by enabling early and precise intervention. The increasing number of immunocompromised patients, including cancer patients, transplant recipients, and individuals with chronic respiratory diseases, has further intensified the need for effective treatment options. Additionally, the growing emphasis on antimicrobial stewardship programs in hospitals and healthcare facilities has led to increased adoption of susceptibility-guided treatment approaches, promoting the use of new-generation antibiotics and adjunct therapies. Research into alternative treatment modalities, such as bacteriophage therapy, host-directed therapies, and immune-boosting biologics, is opening new avenues for combating infections where traditional antibiotics fail. Regulatory support and global initiatives aimed at combating antimicrobial resistance, such as the WHO’s Global Action Plan on AMR, are driving investment in drug discovery and infection control measures. With increasing funding from public and private stakeholders, pharmaceutical companies are accelerating the development of next-generation antibiotics, diagnostics, and adjunctive therapies, positioning the Pseudomonas aeruginosa treatment market for sustained growth in the coming years.

SCOPE OF STUDY:

The report analyzes the Pseudomonas Aeruginosa Infection Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Combination Therapy, Monotherapy); Administration Route (Oral, Nasal, Intravenous)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 39 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â